Form D · Biotechnology
Obsidian Therapeutics, Inc.
Cambridge, MA · CIK 0001723046
Offering snapshot reported Dec 8, 2017 · SEC filing
- Reported sold
- $32.4M Offering amount: $49.9M
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 29, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 8, 2017 | Initial | $32,436,323 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-300326
Source: Form D, filed Dec 8, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Peter Barrett | Director, Executive |
| Jason Gardner | Director |
| Michael Gilman | Director, Executive |
| Karen Hong | Director |
| David Neafus | Executive |
| Carolyn Ng | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1030 Massachusetts Avenue Suite 400
Cambridge, MA, 02138
Cambridge, MA, 02138